NCT06495164 2025-11-25
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Pfizer
Active not recruiting
Clinical Trials
15 trialsNCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT05635357 2025-07-28
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
Brigham and Women's Hospital
Completed
NCT01814397 2024-02-07
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
University of Michigan Rogel Cancer Center
Completed
NCT04852081 2021-04-21
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Unknown
NCT04666805 2020-12-14
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
First Hospital of China Medical University
Unknown
NCT04389424 2020-05-15
NUTRIBREAST
Instituto Jalisciense de Cancerologia
Unknown
NCT01896050 2016-06-28
LOGRIBMET
University of Michigan Rogel Cancer Center
Completed
NCT02023359 2015-12-29
Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
Novartis
Completed
NCT01047358 2015-10-08
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Pfizer
Completed
NCT00776659 2013-11-19
An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
Pfizer
Terminated
NCT01239745 2012-10-31
AromasinĀ® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
Pfizer
Terminated
NCT01155063 2012-10-01
Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients
Pfizer
Terminated
NCT01305239 2012-04-10
ETAPE
Pfizer
Terminated
NCT00932165 2010-07-20
Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Pfizer
Completed